These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 29073582)

  • 1. Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity - A retrospective multicentre study in a large cohort of GIST patients.
    Farag S; van Coevorden F; Sneekes E; Grunhagen DJ; Reyners AKL; Boonstra PA; van der Graaf WT; Gelderblom HJ; Steeghs N
    Eur J Cancer; 2017 Nov; 86():318-325. PubMed ID: 29073582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours.
    Barrios CH; Blackstein ME; Blay JY; Casali PG; Chacon M; Gu J; Kang YK; Nishida T; Purkayastha D; Woodman RC; Reichardt P
    Eur J Cancer; 2015 Nov; 51(16):2423-33. PubMed ID: 26248685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
    Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH
    Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical and medical management of small bowel gastrointestinal stromal tumors: A report of the Dutch GIST registry.
    Boonstra PA; Steeghs N; Farag S; van Coevorden F; Gelderblom H; Grunhagen DJ; Desar IME; van der Graaf WTA; Bonenkamp JJ; Reyners AKL; van Etten B
    Eur J Surg Oncol; 2019 Mar; 45(3):410-415. PubMed ID: 30416078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
    Fu Y; Hao H; Guo L; Yang G; Zhang X
    Oncotarget; 2017 Feb; 8(6):10136-10144. PubMed ID: 28052037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection.
    Guérin A; Sasane M; Keir CH; Gauthier G; Macalalad AR; Wu EQ; Conley AP
    JAMA Oncol; 2015 Sep; 1(6):797-805. PubMed ID: 26204106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
    Verboom MC; Kloth JSL; Swen JJ; van der Straaten T; Bovée JVMG; Sleijfer S; Reyners AKL; Mathijssen RHJ; Guchelaar HJ; Steeghs N; Gelderblom H
    Eur J Cancer; 2017 Nov; 86():226-232. PubMed ID: 29054076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
    Patrikidou A; Domont J; Chabaud S; Ray-Coquard I; Coindre JM; Bui-Nguyen B; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Pérol D; Emile JF; Blay JY; Le Cesne A;
    Eur J Cancer; 2016 Jan; 52():173-80. PubMed ID: 26687836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST).
    Den Hollander D; Van der Graaf WTA; Desar IME; Le Cesne A
    Acta Oncol; 2019 Nov; 58(11):1648-1654. PubMed ID: 31345082
    [No Abstract]   [Full Text] [Related]  

  • 10. Resection of liver metastases in patients with gastrointestinal stromal tumors in the imatinib era: A nationwide retrospective study.
    Seesing MF; Tielen R; van Hillegersberg R; van Coevorden F; de Jong KP; Nagtegaal ID; Verhoef C; de Wilt JH;
    Eur J Surg Oncol; 2016 Sep; 42(9):1407-13. PubMed ID: 27038995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors.
    Gold JS; van der Zwan SM; Gönen M; Maki RG; Singer S; Brennan MF; Antonescu CR; De Matteo RP
    Ann Surg Oncol; 2007 Jan; 14(1):134-42. PubMed ID: 17080234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China.
    Shi YN; Li Y; Wang LP; Wang ZH; Liang XB; Liang H; Zhang L; Li B; Fan LQ; Zhao Q; Ma ZX; Zhao XF; Zhang ZD; Liu Y; Tan BB; Wang D; Wang LL; Hao YJ; Jia N
    Medicine (Baltimore); 2017 Nov; 96(46):e8240. PubMed ID: 29145240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal stromal tumor: 15-years' experience in a single center.
    Wang M; Xu J; Zhang Y; Tu L; Qiu WQ; Wang CJ; Shen YY; Liu Q; Cao H
    BMC Surg; 2014 Nov; 14():93. PubMed ID: 25403624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Affecting Disease-Free Survival in Operated Nonmetastatic Gastrointestinal Stromal Tumors.
    Sakin A; Can O; Arici S; Yasar N; Geredeli C; Demir C; Cihan S
    J Surg Res; 2019 Sep; 241():170-177. PubMed ID: 31026795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
    Farag S; Somaiah N; Choi H; Heeres B; Wang WL; van Boven H; Nederlof P; Benjamin R; van der Graaf W; Grunhagen D; Boonstra PA; Reyners AK; Gelderblom H; Steeghs N
    Eur J Cancer; 2017 May; 76():76-83. PubMed ID: 28284172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and pathological characteristics and their effect on survival in elderly patients with gastrointestinal stromal tumors.
    Molinas Mandel N; Selcukbiricik F; Kanitez M; Yalcin S; Tural D; Erdamar S; Dogusoy G; Demir G
    J BUON; 2016; 21(2):360-5. PubMed ID: 27273945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rectal GIST-Outcomes and viewpoint from a tertiary cancer center.
    Zanwar S; Ostwal V; Sahu A; Jain D; Ramaswamy A; Saklani A; Ramadwar M; Shetty N; Shrikande SV
    Indian J Gastroenterol; 2016 Nov; 35(6):445-449. PubMed ID: 27783353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
    JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.
    Gold JS; Gönen M; Gutiérrez A; Broto JM; García-del-Muro X; Smyrk TC; Maki RG; Singer S; Brennan MF; Antonescu CR; Donohue JH; DeMatteo RP
    Lancet Oncol; 2009 Nov; 10(11):1045-52. PubMed ID: 19793678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.
    Le Cesne A; Ray-Coquard I; Bui BN; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Cioffi A; Emile JF; Chabaud S; Pérol D; Blay JY;
    Lancet Oncol; 2010 Oct; 11(10):942-9. PubMed ID: 20864406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.